ライフサイエンスコーパス: vasculopathy

1 tified 18 patients (43 +/- 15 y, 12 moyamoya vasculopathy).

2 early onset or accelerated cardiac allograft vasculopathy.

3 ficking, alloimmunity, and cardiac allograft vasculopathy.

4 dy-mediated rejection, and chronic allograft vasculopathy.

5 ts showed association with chronic allograft vasculopathy.

6 bout the role of CD16 in promoting allograft vasculopathy.

7 fibrosis of the skin and internal organs and vasculopathy.

8 ly correlate with the severity of arteriolar vasculopathy.

9 ecific Fli1-knockout mice recapitulating SSc vasculopathy.

10 d intracerebral varicella zoster virus (VZV) vasculopathy.

11 icator of graft rejection or coronary artery vasculopathy.

12 flow velocities (>/= 200 cm/s) but no severe vasculopathy.

13 regression of polyps in polypoidal choroidal vasculopathy.

14 ercept in management of polypoidal choroidal vasculopathy.

15 sociated with widespread tissue fibrosis and vasculopathy.

16 o mechanisms of chronic allograft injury and vasculopathy.

17 ence of acute rejection or chronic allograft vasculopathy.

18 r risk, and reduce the incidence of coronary vasculopathy.

19 llograft rejection, also known as transplant vasculopathy.

20 r, could attenuate development of transplant vasculopathy.

21 avitreal aflibercept in polypoidal choroidal vasculopathy.

22 rts an ischemic pathogenesis of this retinal vasculopathy.

23 ctivity attenuates development of transplant vasculopathy.

24 nary arterial hypertension (PAH) is a lethal vasculopathy.

25 en in the presence of only mild angiographic vasculopathy.

26 ft ventricular assist devices and transplant vasculopathy.

27 n C57BL/6 recipients and developed allograft vasculopathy.

28 ronal features without clinically detectable vasculopathy.

29 polyarteritis nodosa (cPAN) and early-onset vasculopathy.

30 ases, such as atherosclerosis and transplant vasculopathy.

31 stenosis, vein graft stenosis, and allograft vasculopathy.

32 degree of peritoneal fibrosis, but not with vasculopathy.

33 of skin and organ fibrosis and obliterative vasculopathy.

34 tly of the breakdown of the BRB and onset of vasculopathy.

35 helial reactivity and induction of pulmonary vasculopathy.

36 actin expression and inflammatory pulmonary vasculopathy.

37 play a hitherto unsuspected role in diabetic vasculopathy.

38 llograft, leading to allograft rejection and vasculopathy.

39 esolution, pulmonary artery obstruction, and vasculopathy.

40 large antibody loads, and chronic allograft vasculopathy.

41 lgia, myelitis, meningoencephalitis, and VZV vasculopathy.

42 ivation and development of cardiac allograft vasculopathy.

43 to halt the progression of cardiac allograft vasculopathy.

44 immune disease characterized by fibrosis and vasculopathy.

45 beneficial effect of cyclophosphamide on SSc vasculopathy.

46 sfunction and is considered to be a systemic vasculopathy.

47 tenuate the development of cardiac allograft vasculopathy.

48 c allograft rejection and coronary allograft vasculopathy.

49 greater risk of developing chronic allograft vasculopathy.

50 ary artery disease, atrial fibrillation, and vasculopathy.

51 h SMAD3 phosphorylation in cardiac allograft vasculopathy.

52 e critical in the pathogenesis of transplant vasculopathy.

53 y also play a role in the development of SCD vasculopathy.

54 nce of phosphorylated SMAD2/3, and degree of vasculopathy.

55 tions are known collectively as the TGF-beta vasculopathies.

56 a group called the smooth muscle contraction vasculopathies.

57 er general anesthesia for a range of retinal vasculopathies.

58 ensin II (Ang-II), are commonly increased in vasculopathies.

59 ities in a variety of vascular disorders and vasculopathies.

60 ole in the development of fibroproliferative vasculopathies.

61 The commonest etiology was HIV-associated vasculopathy (24 [38%]), followed by opportunistic infec

62 g and identifying the regulators of diabetic vasculopathy, a disease that affects hundreds of million

63 yloid angiopathy are the underlying cerebral vasculopathies accounting for the majority of ICH, there

64 t of patients has an associated inflammatory vasculopathy affecting large arteries (giant cell arteri

65 r risk of acute rejection, cardiac allograft vasculopathy after heart transplantation, and potentiall

66 myocardial infarction and cardiac allograft vasculopathy after heart transplantation.

67 ive paracrine factors is a strategy to treat vasculopathies and to promote tissue regeneration.

68 atient with varicella-zoster virus (VZV) CNS vasculopathy and as part of the evaluation, tested his p

69 us (HIV) infection are at risk for premature vasculopathy and cardiovascular disease (CVD).

70 two patients with autosomal dominant retinal vasculopathy and cerebral leukoencephalopathy (previousl

71 es, brain regions from patients with retinal vasculopathy and cerebral leukoencephalopathy that harbo

72 responsible for the progression of allograft vasculopathy and chronic rejection.Recent work has sugge

73 l patients with NAION for systemic survey of vasculopathy and control of modifiable risk factors to p

74 s molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, an

75 6 may be involved in the pathogenesis of SSc vasculopathy and fibrosis.

76 Because intracerebral VZV vasculopathy and giant cell arteritis are strongly assoc

77 as tested using a murine model of transplant vasculopathy and human cells.

78 development, is characterized by glomeruloid vasculopathy and hydrocephalus, and is almost invariably

79 c sclerosis (SSc) is manifested by fibrosis, vasculopathy and immune dysregulation.

80 logical examination of the skin showed graft vasculopathy and occasional C4d deposits in cutaneous ca

81 d deep vessels, leading, as in SOT, to graft vasculopathy and often to graft loss.

82 HIV-associated vasculopathy and opportunistic infections are common cau

83 nal vascular associations leading to retinal vasculopathy and paracentral acute middle maculopathy in

84 pathological vascular remodeling during VZV vasculopathy and persistent inflammation in infected lun

85 lcineurin antagonists reduces posttransplant vasculopathy and prolongs survival following cardiac tra

86 r aneurysm formation in a novel model of NF1 vasculopathy and provide a potential therapeutic target.

87 in humans with SCD and in mice to markers of vasculopathy and pulmonary hypertension.

88 Coronary artery vasculopathy and survival were not significantly impacte

89 de accelerated arterial disease in allograft vasculopathy and systemic autoimmune diseases and involv

90 Abs and complement, including posttransplant vasculopathy and systemic lupus erythematosus.

91 e of effective viral clearance occurs in VZV vasculopathy and VZV infection of the lung is a step tow

92 promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications

93 ssue disorder characterized by autoimmunity, vasculopathy, and extensive cutaneous and visceral fibro

94 d a marked reduction in dermal inflammation, vasculopathy, and fibrosis compared with that seen in th

95 the pathological processes of inflammation, vasculopathy, and fibrosis in human diseases and their a

96 ical features of SSc including autoimmunity, vasculopathy, and fibrosis, and provide a unified diseas

97 time until graft failure, cardiac allograft vasculopathy, and hospitalization for rejection.

98 ed by fibrosis of the skin and inner organs, vasculopathy, and immunological abnormalities.

99 I]) levels in SCD will limit vaso-occlusion, vasculopathy, and inflammation, we used 2 strategies to

100 early-onset systemic inflammation, cutaneous vasculopathy, and pulmonary inflammation.

101 -year AMR/CMR (>/= grade 2), coronary artery vasculopathy, and survival.

102 te macular neuroretinopathy (AMN) or retinal vasculopathy, and that may indicate an underlying pathog

103 -cell-depleted donors developed only minimal vasculopathy, and the alloantibody responses were weaker

104 nifestations of SSc, including inflammation, vasculopathy, and tissue fibrosis, with bleomycin-treate

105 verse events, the mechanisms of drug-induced vasculopathy are not well understood.

106 ification of patients with cardiac allograft vasculopathy are problematic.

107 nction reported in cbs(-/-) mice may reflect vasculopathy as well as neuropathy.

108 for cerebral ischemic injury disease due to vasculopathy associated with ESKD and from their comorbi

109 hat vanin-1/pantetheinase controls fibrosis, vasculopathy, autoimmunity, and oxidative stress in SSc.

110 ncy in mice enables suppression of allograft vasculopathy (AV) after aorta transplantation, a DSA-med

111 DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that aff

112 show that H+LTx attenuates cardiac allograft vasculopathy by decreasing the rate of plaque volume and

113 e etiology of PAH, and may contribute to PAH vasculopathy by enabling inflammatory mediator flux acro

114 inib mesylate enhanced rat cardiac allograft vasculopathy, cardiac fibrosis, and late allograft loss

115 Coronary allograft vasculopathy (CAV) assessed by coronary intravascular ul

116 Cardiac allograft vasculopathy (CAV) has a high prevalence among patients

117 raphy (CCTA) for detecting cardiac allograft vasculopathy (CAV) in comparison with conventional coron

118 y) have been associated with coronary artery vasculopathy (CAV) in pediatric heart transplant (HT) re

119 Cardiac allograft vasculopathy (CAV) is a major contributor of heart trans

120 Cardiac allograft vasculopathy (CAV) is a major limitation in long-term gr

121 Cardiac allograft vasculopathy (CAV) is an increasingly important complica

122 Cardiac allograft vasculopathy (CAV) is associated with intragraft B cell

123 Because cardiac allograft vasculopathy (CAV) is the major cause of late mortality

124 Cardiac allograft vasculopathy (CAV) is the preeminent cause of late cardi

125 Although cardiac allograft vasculopathy (CAV) is typically characterized by diffuse

126 Chronic allograft vasculopathy (CAV) limits the lifespan of pediatric hear

127 Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality

128 Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-te

129 Cardiac allograft vasculopathy (CAV) remains the leading cause of morbidit

130 onance (CMR) for detecting cardiac allograft vasculopathy (CAV) using contemporary invasive epicardia

131 tural killer (NK) cells in cardiac allograft vasculopathy (CAV) was suggested by our earlier observat

132 ovirus (CMV) infection and cardiac allograft vasculopathy (CAV) were conducted on patients transplant

133 ovirus (CMV) infection and cardiac allograft vasculopathy (CAV) were conducted on patients transplant

134 antation and indicators of chronic allograft vasculopathy (CAV) were quantified.

135 E for recipient mortality, cardiac allograft vasculopathy (CAV), and primary graft failure (PGF).

136 ach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration

137 cells experienced the same chronic allograft vasculopathy (CAV), which is a pathognomonic feature of

138 and future development of cardiac allograft vasculopathy (CAV).

139 nt angiographic grading of cardiac allograft vasculopathy (CAV); however, no data exist on the utilit

140 erapy (mucosal necrosis, osteoradionecrosis, vasculopathy, cerebral radionecrosis) and surgery (wound

141 Pulmonary arterial hypertension (PAH) is a vasculopathy characterized by enhanced pulmonary artery

142 rterial hypertension (PAH) is an obstructive vasculopathy characterized by excessive pulmonary artery

143 Importance: Vasculopathy characterized by functional and structural

144 l/fl) recipients developed severe transplant vasculopathy (chronic rejection).

145 the native heart in allografts with chronic vasculopathy compared to isograft controls on day 28 (P

146 afts, with reduced cellular infiltration and vasculopathy compared with wild type cardiac grafts.

147 Historically, polypoidal choroidal vasculopathy complexes are less responsive to anti-vascu

148 s of (1) a nitric oxide deficiency state and vasculopathy consequent to intravascular hemolysis, (2)

149 agnosis (OR=200; P=0.04), and severe chronic vasculopathy (cv>/=2) on index biopsy (OR=50; P=0.06).

150 giopathy (lobar structures) and hypertensive vasculopathy (deep brain structures).

151 ally, in a murine model of cardiac allograft vasculopathy, depletion of donor CD4 nT-regs before orga

152 support, in a model of alloantibody-mediated vasculopathy, depletion of NK cells from a C57BL/6 recip

153 raft survival and to delay cardiac allograft vasculopathy development and antidonor alloAb production

154 ses the IVW findings of various intracranial vasculopathies, differentiating characteristics and indi

155 logic placental blood vessel lesion decidual vasculopathy (DV) has been shown to predict adverse preg

156 schemia/reperfusion injury, stroke, diabetic vasculopathy, epilepsy and cancer.

157 histologic signs of severe chronic allograft vasculopathy eventually led to amputation of the graft.

158 ease groups suggests a key role in pulmonary vasculopathy for the first time.

159 mary graft dysfunction and cardiac allograft vasculopathy-free survival did not significantly differ

160 t bleeding, rejection, and cardiac allograft vasculopathy-free survival.

161 xposure on the ln-scale) of fetal thrombotic vasculopathy (FTV) both with increasing PM2.5 [adjusted

162 apy, transcranial Doppler-confirmed cerebral vasculopathy), genotype, gender, and race were evaluated

163 positively associated with cardiac allograft vasculopathy grade.

164 A novel MRA vasculopathy grading scale demonstrated frequent severe

165 The novel SWiTCH vasculopathy grading scale warrants validation testing a

166 We found that a patient with VZV CNS vasculopathy had antibody that neutralized interferon (I

167 d macular degeneration, polypoidal choroidal vasculopathy has differing clinical manifestations and t

168 In addition to his severe cutaneous vasculopathy, he experienced recurrent fevers, interstit

169 s variables to models with cardiac allograft vasculopathy, history of rejection, time since transplan

170 .001) after adjustment for cardiac allograft vasculopathy, history of rejection, time since transplan

171 transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute

172 vitreal aflibercept for polypoidal choroidal vasculopathy in 21 eyes was conducted.

173 VE21 induction, EC activation, and allograft vasculopathy in a humanized mouse model.

174 pulmonary angiography (DECTPA) in revealing vasculopathy in coronavirus disease 2019 (COVID-19) has

175 mechanism that leads to BK channelopathy and vasculopathy in diabetes.

176 3 were identified as key drivers of diabetic vasculopathy in human blood vessels.

177 oonotic viruses that show various degrees of vasculopathy in humans.

178 also exist in patients with STING-associated vasculopathy in infancy (SAVI).

179 this gene results in microcephaly-associated vasculopathy in mice and humans.

180 nted vascular repair, and worsened occlusive vasculopathy in mice.

181 imb and scalp defects might also be due to a vasculopathy in NOTCH1-related AOS.

182 rcts in either treatment group, but worsened vasculopathy in one participant who received standard tr

183 tion of retinal telangiectasia or Coats-like vasculopathy in patients with CRB1 mutations that are th

184 s of subependymal cysts and lenticulostriate vasculopathy in postnatal imaging.

185 and glaucoma (PXG) showed deep peripapillary vasculopathy in pseudoexfoliation syndrome.

186 xidation, may be central to the evolution of vasculopathy in SCD and may suggest therapeutic modaliti

187 PBV/PAenh may be an important marker of vasculopathy in severe COVID-19 pneumonia even in the ab

188 Endothelin-1 promotes vasculopathy in systemic sclerosis after macitentan, an

189 thologic analysis together with the expected vasculopathy in the inner retina.

190 edoid rash, hepatosplenomegaly, and systemic vasculopathy in three unrelated patients.

191 vel mechanism contributes to protection from vasculopathy in transplanted organs treated with exogeno

192 f KLF15 exhibited an aggressive inflammatory vasculopathy in two distinct models of vascular disease:

193 (s) of RR6-induced attenuation of transplant vasculopathy in vivo.

194 Liver injury leads to a vasculopathy in which post-translational modifications o

195 ortuosity were associated with extracoronary vasculopathy including fibromuscular dysplasia (P<0.05 f

196 es of SCAD are associated with extracoronary vasculopathy, including fibromuscular dysplasia.

197 ical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulce

198 lted in amelioration of HFD-induced decidual vasculopathy independent of offspring genotype and sex.

199 trate lasting gene expression changes in the vasculopathies initiated by previous exposure to high gl

200 velop systemic inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin

201 ications that may extend beyond BAS to other vasculopathies involving vascular remodeling.

202 ccurate and timely diagnosis of intracranial vasculopathies is important due to significant risk of m

203 This review evaluates evidence that SCD vasculopathy is a harbinger for organ dysfunction and re

204 Cardiac allograft vasculopathy is a key prognostic determinant after heart

205 Development of transplant vasculopathy is a major cause of graft loss and mortalit

206 Cardiac allograft vasculopathy is a multifactorial process in which the im

207 Polypoidal choroidal vasculopathy is a variant of choroidal neovascularizatio

208 Polypoidal choroidal vasculopathy is more prevalent in anti-VEGF-resistant ey

209 Polypoidal choroidal vasculopathy is more prevalent in Asian patients with ex

210 Cardiac allograft vasculopathy is the major cause of late allograft loss a

211 d-organ damage, partly related to a systemic vasculopathy, is increasingly recognised.

212 To exclude vasculopathy, it is important to measure the integrity o

213 dings would support the concept of pulmonary vasculopathy leading to altered ventilation perfusion ma

214 ese blood vessel organoids to model diabetic vasculopathy led to the identification of a new potentia

215 Furthermore, subtypes of HIV-associated vasculopathy may manifest as a result of an immune recon

216 on fraction (n=104, 85%), coronary allograft vasculopathy (n=86, 70%), prior rejection (n=76, 62%), p

217 Coats-like exudative vasculopathy, not previously reported in JNCL, was obser

218 had an increase in decidual inflammation and vasculopathy occurring together.

219 0.21-0.65; P=0.0005), incidence of coronary vasculopathy (odds ratio, 0.33; 95% confidence interval,

220 aldosterone may contribute to the pulmonary vasculopathy of hypoxia.

221 ardi-Goutieres syndrome and STING-associated vasculopathy of infancy (SAVI).

222 ew therapeutic strategy for the inflammatory vasculopathy of SCD.

223 ications of heart transplantation (HTx), the vasculopathy of the allograft (CAV), a phenomenon of chr

224 The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknow

225 hree features of SSc, including fibrosis and vasculopathy of the skin and lung, B-cell activation and

226 e, which suggests that strokes are caused by vasculopathy of the small and medium-size cerebral arter

227 the application and findings of the various vasculopathies on IVW can help guide diagnostic and ther

228 base was searched for patients with moyamoya vasculopathy or atherosclerotic cerebrovascular disease

229 rom early-onset recurrent stroke to systemic vasculopathy or vasculitis.

230 termediate-term mortality, cardiac allograft vasculopathy, or primary graft failure rates in hearts a

231 differences between primary cause of death, vasculopathy, or rejection.

232 tal abruption, infarction, hypoxia, decidual vasculopathy, or thrombosis of fetal vessels (n = 240 ca

233 unologic and graft survival as well as graft vasculopathy outcomes after VCA.

234 loss even in children with mild angiographic vasculopathy (p < 0.0001).

235 matching groups in the frequency of coronary vasculopathy (P=0.19) or rejection in the first post-tra

236 d in 7 cases, including polypoidal choroidal vasculopathy (PCV) and macular fibrosis or atrophy.

237 the subtypes according polypoidal choroidal vasculopathy (PCV) and non-PCV subtypes.

238 Patients with polypoidal choroidal vasculopathy (PCV) had a worse final outcome.

239 Polypoidal choroidal vasculopathy (PCV) is a common choroidal vascular diseas

240 Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular age-relat

241 cal neovascular AMD and polypoidal choroidal vasculopathy (PCV) over 12-months.

242 Polypoidal choroidal vasculopathy (PCV), a subtype of 'wet' age-related macul

243 predict retreatment in polypoidal choroidal vasculopathy (PCV).

244 of the pathogenesis of polypoidal choroidal vasculopathy (PCV).

245 mab in the treatment of polypoidal choroidal vasculopathy (PCV).

246 Eyes with polypoidal choroidal vasculopathy previously treated with ranibizumab and bev

247 Varicella-zoster virus (VZV) vasculopathy produces stroke, giant cell arteritis, and

248 inhibitor use, attenuating cardiac allograft vasculopathy progression and reducing cytomegalovirus in

249 xplained by attenuation of cardiac allograft vasculopathy progression.

250 DA2 results in variable autoinflammation and vasculopathy (recurrent fevers, livedo reticularis, poly

251 y were all followed up for a severe cerebral vasculopathy related to sickle cell disease.

252 ate, previously documented cardiac allograft vasculopathy), relative perfusion defects, mean myocardi

253 Cardiac allograft vasculopathy remains a major limiting factor in the long

254 ial cells and/or pericytes leads to diabetic vasculopathy remains largely unknown.

255 ronic rejection leading to cardiac allograft vasculopathy, remains a major cause of graft loss.

256 intermediate/posterior/panuveitis, systemic vasculopathy, retinal vascular disease, or active inflam

257 arteriovenous fistula and cardiac allograft vasculopathy samples to assess the role of LMO7 in neoin

258 arteriovenous fistula and cardiac allograft vasculopathy samples, and inversely correlates with SMAD

259 -treated grafts had higher cardiac allograft vasculopathy severity scores during treatment relative t

260 ion fraction, cerebral blood flow, degree of vasculopathy, severity of anaemia, and presence of prior

261 e, elicits a disease-modifying effect on SSc vasculopathy, such as fostering microvascular de-remodel

262 tion (AMR) resulting in transplant allograft vasculopathy (TAV) is the major obstacle for long-term s

263 significant/fatal graft rejection, coronary vasculopathy, terminal cancer, and overall survival.

264 r-Degos disease) is a rare thrombo-occlusive vasculopathy that can affect multiple organ systems.

265 l retinal function before the development of vasculopathy, thereby resulting in visual deficits.

266 Transplant vasculopathy (TV) is a major cause for late graft loss a

267 Transplant vasculopathy (TV) represents a major obstacle to long-te

268 crophage infiltrate, but no evidence for the vasculopathy typically associated with preeclampsia.CONC

269 Similarly, cardiac allograft vasculopathy up to 5 years and primary graft failure up

270 se heart allografts with alloimmune-mediated vasculopathy upregulated expression of apelin in arterie

271 (Prevention of Cardiac Allograft Vasculopathy Using Rituximab [Rituxan] Therapy in Cardia

272 The CTOT-11 (Prevention of Cardiac Allograft Vasculopathy Using Rituximab Therapy in Cardiac Transpla

273 iography (CTA) to rule out cardiac allograft vasculopathy versus 16 patients without transplants who

274 Polypoidal choroidal vasculopathy was diagnosed in 50% (60/120 eyes) of eyes

275 Polypoidal choroidal vasculopathy was diagnosed using indocyanine green angio

276 atment with an apelin receptor agonist after vasculopathy was established markedly reduced progressio

277 rejection or development of coronary artery vasculopathy was not seen.

278 Polypoidal choroidal vasculopathy was noted in 51.6% (81/157) of eyes with we

279 Polypoidal choroidal vasculopathy was noted to have a prevalence of 45.1% (11

280 nism by which cyclophosphamide mitigates SSc vasculopathy, we employed endothelial cell-specific Fli1

281 atous proliferation and polypoidal choroidal vasculopathy were excluded.

282 sponses and blocked development of allograft vasculopathy, whereas class II specific Tregs were ineff

283 rus-infected arteries from patients with VZV vasculopathy, while downregulation of MHC-I prevents vir

284 ial new insights into the nature of diabetic vasculopathy will be discussed.

285 dence of active rejection or coronary artery vasculopathy with 35 age-matched normal controls.

286 Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a ra

287 plasticity of EdCs could contribute to link vasculopathy with fibrosis.

288 ne deaminase, can cause polyarteritis nodosa vasculopathy with highly varied clinical expression.

289 sickle cell disease (SCD) leads to a chronic vasculopathy with multiple organ involvement.

290 ed stimulator of interferon genes-associated vasculopathy with onset in infancy (SAVI) caused by gain

291 lator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) develop system

292 STING-associated vasculopathy with onset in infancy (SAVI) is an autoinfl

293 NG N154S in humans) develop STING-associated vasculopathy with onset in infancy (SAVI), a severe pedi

294 nflammatory disease, called STING-associated vasculopathy with onset in infancy (SAVI), affects child

295 e I interferonopathy called STING-associated vasculopathy with onset in infancy (SAVI).

296 identified in patients with STING-associated vasculopathy with onset in infancy (SAVI).

297 inflammatory disease called STING-associated vasculopathy with onset in infancy that is associated wi

298 seen in human patients with STING-associated vasculopathy with onset in infancy.

299 outieres syndrome (AGS) and STING-associated vasculopathy with onset of infancy (SAVI).

300 IIDeltak-fib model, which develops pulmonary vasculopathy with pulmonary hypertension that is exacerb